vs
Side-by-side financial comparison of Dayforce (DAY) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $481.6M, roughly 1.5× Dayforce). Dayforce runs the higher net margin — -40.9% vs -104.7%, a 63.9% gap on every dollar of revenue. On growth, Dayforce posted the faster year-over-year revenue change (9.5% vs -3.7%). Over the past eight quarters, Dayforce's revenue compounded faster (9.8% CAGR vs -2.9%).
Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
DAY vs QDEL — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $481.6M | $699.9M |
| Net Profit | $-196.8M | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | 6.3% | -100.7% |
| Net Margin | -40.9% | -104.7% |
| Revenue YoY | 9.5% | -3.7% |
| Net Profit YoY | -9940.0% | -3583.4% |
| EPS (diluted) | $-1.23 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $481.6M | $699.9M | ||
| Q2 25 | $464.7M | $613.9M | ||
| Q1 25 | $481.8M | $692.8M | ||
| Q4 24 | $465.2M | $707.8M | ||
| Q3 24 | $440.0M | $727.1M | ||
| Q2 24 | $423.3M | $637.0M | ||
| Q1 24 | $431.5M | $711.0M | ||
| Q4 23 | $399.7M | $742.6M |
| Q3 25 | $-196.8M | $-733.0M | ||
| Q2 25 | $21.3M | $-255.4M | ||
| Q1 25 | $14.9M | $-12.7M | ||
| Q4 24 | $10.8M | $-178.4M | ||
| Q3 24 | $2.0M | $-19.9M | ||
| Q2 24 | $-1.8M | $-147.7M | ||
| Q1 24 | $7.1M | $-1.7B | ||
| Q4 23 | $45.6M | $7.0M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 47.0% | — | ||
| Q3 24 | 45.8% | — | ||
| Q2 24 | 44.1% | — | ||
| Q1 24 | 47.6% | — | ||
| Q4 23 | 42.5% | — |
| Q3 25 | 6.3% | -100.7% | ||
| Q2 25 | 9.1% | -29.4% | ||
| Q1 25 | 6.4% | 4.7% | ||
| Q4 24 | 6.1% | -14.2% | ||
| Q3 24 | 4.7% | 2.1% | ||
| Q2 24 | 3.3% | -18.4% | ||
| Q1 24 | 9.4% | -247.3% | ||
| Q4 23 | 9.7% | 5.4% |
| Q3 25 | -40.9% | -104.7% | ||
| Q2 25 | 4.6% | -41.6% | ||
| Q1 25 | 3.1% | -1.8% | ||
| Q4 24 | 2.3% | -25.2% | ||
| Q3 24 | 0.5% | -2.7% | ||
| Q2 24 | -0.4% | -23.2% | ||
| Q1 24 | 1.6% | -239.9% | ||
| Q4 23 | 11.4% | 0.9% |
| Q3 25 | $-1.23 | $-10.78 | ||
| Q2 25 | $0.13 | $-3.77 | ||
| Q1 25 | $0.09 | $-0.19 | ||
| Q4 24 | $0.07 | $-2.54 | ||
| Q3 24 | $0.01 | $-0.30 | ||
| Q2 24 | $-0.01 | $-2.20 | ||
| Q1 24 | $0.04 | $-25.50 | ||
| Q4 23 | $0.29 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $627.6M | $98.1M |
| Total DebtLower is stronger | $631.1M | $2.5B |
| Stockholders' EquityBook value | $2.7B | $2.0B |
| Total Assets | $8.7B | $5.7B |
| Debt / EquityLower = less leverage | 0.23× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $627.6M | $98.1M | ||
| Q2 25 | $625.2M | $151.7M | ||
| Q1 25 | $557.3M | $127.1M | ||
| Q4 24 | $579.7M | $98.3M | ||
| Q3 24 | $494.1M | $143.7M | ||
| Q2 24 | $465.4M | $107.0M | ||
| Q1 24 | $392.5M | $78.5M | ||
| Q4 23 | $570.3M | $167.3M |
| Q3 25 | $631.1M | $2.5B | ||
| Q2 25 | $631.8M | $2.1B | ||
| Q1 25 | $632.4M | $2.1B | ||
| Q4 24 | $1.2B | $2.1B | ||
| Q3 24 | $1.2B | $2.2B | ||
| Q2 24 | $1.2B | $2.2B | ||
| Q1 24 | $1.2B | $2.2B | ||
| Q4 23 | $1.2B | $2.3B |
| Q3 25 | $2.7B | $2.0B | ||
| Q2 25 | $2.7B | $2.8B | ||
| Q1 25 | $2.6B | $3.0B | ||
| Q4 24 | $2.5B | $3.0B | ||
| Q3 24 | $2.6B | $3.2B | ||
| Q2 24 | $2.5B | $3.2B | ||
| Q1 24 | $2.4B | $3.3B | ||
| Q4 23 | $2.4B | $5.0B |
| Q3 25 | $8.7B | $5.7B | ||
| Q2 25 | $8.5B | $6.4B | ||
| Q1 25 | $9.5B | $6.5B | ||
| Q4 24 | $9.1B | $6.4B | ||
| Q3 24 | $8.1B | $6.8B | ||
| Q2 24 | $9.0B | $6.7B | ||
| Q1 24 | $10.8B | $6.7B | ||
| Q4 23 | $9.0B | $8.6B |
| Q3 25 | 0.23× | 1.23× | ||
| Q2 25 | 0.23× | 0.74× | ||
| Q1 25 | 0.24× | 0.70× | ||
| Q4 24 | 0.47× | 0.72× | ||
| Q3 24 | 0.47× | 0.68× | ||
| Q2 24 | 0.49× | 0.70× | ||
| Q1 24 | 0.50× | 0.68× | ||
| Q4 23 | 0.50× | 0.45× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.2M | $-45.5M |
| Free Cash FlowOCF − Capex | — | $-94.7M |
| FCF MarginFCF / Revenue | — | -13.5% |
| Capex IntensityCapex / Revenue | — | 7.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $31.2M | $-45.5M | ||
| Q2 25 | $112.7M | $-46.8M | ||
| Q1 25 | $49.6M | $65.6M | ||
| Q4 24 | $81.0M | $63.7M | ||
| Q3 24 | $91.8M | $117.9M | ||
| Q2 24 | $99.2M | $-97.9M | ||
| Q1 24 | $9.1M | $-700.0K | ||
| Q4 23 | $89.9M | $80.4M |
| Q3 25 | — | $-94.7M | ||
| Q2 25 | — | $-84.3M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | — | $71.4M | ||
| Q2 24 | — | $-133.2M | ||
| Q1 24 | — | $-66.8M | ||
| Q4 23 | — | $31.8M |
| Q3 25 | — | -13.5% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -9.4% | ||
| Q4 23 | — | 4.3% |
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 9.3% | ||
| Q4 23 | — | 6.5% |
| Q3 25 | — | — | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | 3.33× | — | ||
| Q4 24 | 7.50× | — | ||
| Q3 24 | 45.90× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.28× | — | ||
| Q4 23 | 1.97× | 11.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
